William Blair Comments on CVRx’s Q1 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – Equities researchers at William Blair issued their Q1 2027 earnings per share (EPS) estimates for shares of CVRx in a report issued on Thursday, November 6th. William Blair analyst B. Vazquez expects that the company will post earnings per share of ($0.45) for the quarter. The consensus estimate for CVRx’s current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx’s Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.43) EPS and FY2027 earnings at ($1.76) EPS.

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald upped their price target on shares of CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday. Canaccord Genuity Group increased their target price on shares of CVRx from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of CVRx in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, CVRx currently has an average rating of “Moderate Buy” and an average target price of $13.17.

CVRx Stock Performance

Shares of NASDAQ CVRX traded down $1.01 during trading hours on Friday, reaching $9.04. 168,204 shares of the stock were exchanged, compared to its average volume of 290,930. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. The stock’s fifty day simple moving average is $8.70 and its 200 day simple moving average is $7.52. CVRx has a 52 week low of $4.30 and a 52 week high of $18.55. The firm has a market capitalization of $236.41 million, a price-to-earnings ratio of -4.33 and a beta of 1.28.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.01. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The company had revenue of $14.69 million for the quarter, compared to analyst estimates of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC bought a new stake in shares of CVRx during the 1st quarter valued at approximately $28,000. Mount Lucas Management LP bought a new position in CVRx during the second quarter worth $30,000. Intech Investment Management LLC bought a new position in shares of CVRx in the 2nd quarter worth about $59,000. Whittier Trust Co. bought a new stake in CVRx in the first quarter worth approximately $73,000. Finally, AlphaQuest LLC lifted its position in shares of CVRx by 725.4% during the 1st quarter. AlphaQuest LLC now owns 6,108 shares of the company’s stock valued at $75,000 after acquiring an additional 5,368 shares during the period. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.